semaglutide 5ml vial Is this the amount I

Mar 2024;75(2):122-133

Ozempic was approved first in 2017 as a Type 1 diabetes treatment

GLP-1

doi: 10.2337/dc23-S009 [DOI] [PMC free article] [PubMed] [Google Scholar] 9

In the first sensitivity analysis comparing the risk of incident NAION in persons with T2D treated with SGLT2 inhibitors alone ( n = 40,206, reference), once-weekly semaglutide alone ( n = 71,658), and once-weekly semaglutide and SGLT2 inhibitors combined ( n = 45,401), we observed 6 events in 82,877 person-years, 36 events in 178,868 person-years, and 31 events in 119,106 person-years, respectively, corresponding to adjusted HR of 242 (95% CI 097 606) and 262 (95% CI 102674) for once-weekly semaglutide without and with SGLT2 inhibitors in a multivariable model adjusted for sex, age, marital status, duration of diabetes, hemoglobin A1c, estimated glomerular filtration rate, cardiovascular disease, use of insulin, use of cholesterol-lowering medicine, and use of blood pressure lowering medicine

Two classes of prescription medications frequently discussed are the GLP-1 receptor agonists (including Semaglutide, Ozempic, and Wegovy) and the stimulant phentermine